PT1973527E - Processos de produção de formulações farmacêuticas à base de partículas destinadas a administração parentérica - Google Patents

Processos de produção de formulações farmacêuticas à base de partículas destinadas a administração parentérica Download PDF

Info

Publication number
PT1973527E
PT1973527E PT06840263T PT06840263T PT1973527E PT 1973527 E PT1973527 E PT 1973527E PT 06840263 T PT06840263 T PT 06840263T PT 06840263 T PT06840263 T PT 06840263T PT 1973527 E PT1973527 E PT 1973527E
Authority
PT
Portugal
Prior art keywords
blend
particles
parenteral administration
processes
pharmaceutical agent
Prior art date
Application number
PT06840263T
Other languages
English (en)
Inventor
Donald E Chickering
David Altreuter
Howard Bernstein
Luis Brito
Olinda C Carneiro
Eric K Huang
Shaina Brito
Rajeev Jain
Sridhar Narasimhan
Namrata Pandit
Julie A Straub
Original Assignee
Acusphere Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acusphere Inc filed Critical Acusphere Inc
Publication of PT1973527E publication Critical patent/PT1973527E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT06840263T 2005-12-15 2006-12-14 Processos de produção de formulações farmacêuticas à base de partículas destinadas a administração parentérica PT1973527E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75046105P 2005-12-15 2005-12-15

Publications (1)

Publication Number Publication Date
PT1973527E true PT1973527E (pt) 2010-01-04

Family

ID=38163638

Family Applications (1)

Application Number Title Priority Date Filing Date
PT06840263T PT1973527E (pt) 2005-12-15 2006-12-14 Processos de produção de formulações farmacêuticas à base de partículas destinadas a administração parentérica

Country Status (10)

Country Link
US (1) US20070178165A1 (pt)
EP (1) EP1973527B1 (pt)
JP (1) JP2009519973A (pt)
AT (1) ATE444736T1 (pt)
CA (1) CA2631494A1 (pt)
DE (1) DE602006009710D1 (pt)
DK (1) DK1973527T3 (pt)
ES (1) ES2334164T3 (pt)
PT (1) PT1973527E (pt)
WO (1) WO2007070852A2 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014MN00380A (pt) 2006-06-30 2015-06-19 Iceutica Pty Ltd
TWI405590B (zh) * 2007-04-06 2013-08-21 Activus Pharma Co Ltd 微粉碎化有機化合物粒子之製法
US8741918B2 (en) * 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
US20100035886A1 (en) * 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
WO2009073215A1 (en) * 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
WO2010002613A2 (en) * 2008-07-02 2010-01-07 3M Innovative Properties Company Method of making a dry powder pharmaceutical composition
MY177537A (en) * 2009-04-24 2020-09-17 Iceutica Pty Ltd Production of encapsulated nanoparticles at commercial scale
SG175308A1 (en) * 2009-04-24 2011-11-28 Iceutica Pty Ltd Method for improving the dissolution profile of a biologically active material
AU2014208310C1 (en) * 2009-04-24 2020-01-23 Iceutica Pty Ltd A Novel Formulation of Diclofenac
EP3290030A1 (en) * 2009-04-24 2018-03-07 Iceutica Pty Ltd. Diclofenac formulation
DK2421513T3 (en) 2009-04-24 2018-03-26 Iceutica Pty Ltd UNKNOWN FORMULATION WITH INDOMETHACIN
BRPI1012980A2 (pt) * 2009-05-19 2016-03-29 Vivia Biotech Sl dispositivo e métodos para analisar a capacidade de resposta celular e a resposta de células neoplásticas a drogas
WO2012094381A2 (en) 2011-01-05 2012-07-12 Hospira, Inc. Spray drying vancomycin
KR20140041453A (ko) 2011-02-25 2014-04-04 사우스다코타주립대학 국소적 전달을 위한 단백질 나노 캐리어
US20130172271A1 (en) * 2012-01-04 2013-07-04 Cynthia Fragale Pharmaceutical Spray Drying
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
CN104288104A (zh) * 2014-09-24 2015-01-21 万特制药(海南)有限公司 奥卡西平干混悬剂及其制备方法
EP3233055A1 (en) * 2014-12-20 2017-10-25 Troikaa Pharmaceuticals Ltd Injectable formulations of paracetamol
WO2020023507A1 (en) * 2018-07-23 2020-01-30 Cornell University Natural fluorescent polyhedral amino acid crystals for efficient entrapment and systemic delivery of hydrophobic small molecules
JP2022506128A (ja) 2018-10-30 2022-01-17 ビーエーエスエフ ソシエタス・ヨーロピア 活性材料が装填された微粒子を製造する方法
CN111904947A (zh) * 2019-05-07 2020-11-10 江苏恒瑞医药股份有限公司 一种注射用药物组合物及其制备方法
BR112021023788A2 (pt) 2019-07-12 2022-02-08 Basf Se Processo para produzir micropartículas, composição de micropartículas, produto, e, uso da composição
CN113440529B (zh) * 2020-03-25 2023-11-14 江苏恒瑞医药股份有限公司 一种可注射的药物组合物及其制备方法
US20220168272A1 (en) * 2021-02-22 2022-06-02 Gholamhossein Yousefi Preparation of soluble form of carvedilol
WO2024038046A1 (en) 2022-08-18 2024-02-22 Basf Se Process for producing microparticles
WO2024115355A1 (en) 2022-11-28 2024-06-06 Basf Se Conjugates of polysaccharides and hydrophobic compounds as emulsion stabilizers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5370878A (en) * 1993-09-30 1994-12-06 Hallmark Pharmaceuticals, Inc. Method for preparing a direct compression granulated acetaminophen composition
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5811406A (en) * 1995-06-07 1998-09-22 Regents Of The University Of California Dry powder formulations of polynucleotide complexes
US7029700B2 (en) * 2000-01-14 2006-04-18 Brown University Research Foundation Micronized freeze-dried particles
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
WO2004064752A2 (en) * 2003-01-22 2004-08-05 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles

Also Published As

Publication number Publication date
ES2334164T3 (es) 2010-03-05
WO2007070852A2 (en) 2007-06-21
WO2007070852A3 (en) 2007-11-01
ATE444736T1 (de) 2009-10-15
DK1973527T3 (da) 2010-02-01
EP1973527B1 (en) 2009-10-07
US20070178165A1 (en) 2007-08-02
DE602006009710D1 (de) 2009-11-19
EP1973527A2 (en) 2008-10-01
JP2009519973A (ja) 2009-05-21
CA2631494A1 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
PT1973527E (pt) Processos de produção de formulações farmacêuticas à base de partículas destinadas a administração parentérica
WO2007070843A3 (en) Processes for making particle-based pharmaceutical formulations for oral administration
WO2007070851A3 (en) Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
WO2011112900A3 (en) Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
WO2009122301A3 (en) Rasagiline mesylate particles and process for the preparation thereof
WO2009026461A3 (en) Thermo-kinetic mixing for pharmaceutical applications
WO2006113505A3 (en) Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
UA90708C2 (ru) Таблетки с улучшенной дисперсностью лекарственного вещества
WO2009032246A3 (en) Particulate compositions for delivery of poorly soluble drugs
CA2430318A1 (en) Powder formulation and method for producing the same
WO2007150075A3 (en) Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
WO2007133751A3 (en) Base-stabilized polyorthoester formulations
WO2008024485A3 (en) Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent
UA95088C2 (ru) Композиция, которая содержит наночастички связанные с биосовместимым полимером противоракового агента и снижает аллопецию при химиотерапии, способ ее получения
WO2008069938A3 (en) Method of forming a tablet comprising pre-blend of ibupropen and silicon dioxide
WO2007120838A3 (en) Rapidly disintegrating solid oral dosage form of liquid dispersions
AU2014226192A8 (en) Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles
WO2014167579A3 (en) Stable pharmaceutical compositions of tadalafil
WO2007056177A3 (en) T315a and f317i mutations of bcr-abl kinase domain
HK1120739A1 (en) Oral solid pharmaceutical formulation of the tribulin inhibitor indibulin
WO2006030301A8 (en) Cilostazol- containing pharmaceutical composition based on particles of less than 50 micrometers
WO2007089926A3 (en) Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
WO2007128495A3 (en) Solid pharmaceutical composition of gabapentin
WO2011146852A8 (en) Foams or particles for applications such as drug delivery
CN106913537A (zh) 一种醋酸阿比特龙舌下片剂及其制备方法